Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory myeloma.

There is an interesting study of BT062, explains Kelly. It is an antibody-drug conjugate with the chemotherapy attached to CD138, which is a marker in myeloma cells. This combination is with lenalidomide and, so far, relapsed/refractory patients with multiple myeloma patients are experiencing active responses.

We are going to continue to follow these patients for progression, states Kelly. We have not yet reached a median progression free survival, but prolonged durable responses to the combination treatment have been seen.

Videos

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.

Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

This is a phase I clinical trial evaluting an oncolytic virus reolysin in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

The goal is to find the maximum tolerated dose of reolysin. Preliminary results regarding immune system activation are promising.

The study is currently ongoing. Next steps include expanding the study to include more patients to confirm safety.

Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses a study examining racial disparities in patients with multiple myeloma.

Kelly and his colleagues conducted a review of the Surveillance Epidemiology and End Results (SEER) database to look at the differences in outcomes among different ethnic groups in the U.S. The researchers examined patients diagnosed after 1992 and compared their outcome to those diagnosed after 1996, and then compared those to outcomes of patients diagnosed after 2003 to see if there were any improvements in outcomes among specific ethnic groups at different time points.

According to Kelly, they found that outcomes generally continued to improve over time, particularly since 2003, with the introduction of several novel agents. For younger patients, outcomes improved after 1996 with the introduction of autologous stem cell transplant, though not all patients benefited because not all of them qualified for transplant.

In terms of ethnic disparities, the results showed that Hispanic patients are diagnosed at a younger age and continue to have inferior outcomes in terms of responses to treatments. African American patients reportedly had the highest incidence of disease, while Asian patients had the lowest incidence and best outcome with treatments.

Moreover, some new trends have emerged over time, with white patients showing improved median overall survival (OS), and elderly patients demonstrating modest benefits in OS since the advent of novel therapeutics.

Kevin R. Kelly, MD, PhD

Articles

Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma

Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

Dr. Kelly on Racial Disparities in Multiple Myeloma